Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.40 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.37 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1183661 | 1.00 | TSHR (0.43) | TSHRGABRR1CYP1A2FOLH1NAALAD2 | |
| SCHEMBL2623478 | 1.00 | TSHR (0.43) | TSHRGABRR1CYP1A2FOLH1NAALAD2 | |
| Hydrochloric Acid SCHEMBL8749340 | 0.98 | TSHR (0.42) | TSHRGABRR1CYP1A2FOLH1NAALAD2 | |
| Dimethyl Succinate SCHEMBL28142389 | 0.82 | TSHR (0.54) | TSHRCYP1A2NAALAD2HSD17B10SLC1A1 | |
| SCHEMBL186433 | 0.80 | TSHR (0.43) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL1878449 | 0.80 | TSHR (0.43) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL774101 | 0.80 | TSHR (0.43) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL17226123 | 0.80 | MGAM (0.46) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL4429511 | 0.80 | GABRR1 (0.41) | GABRR1CYP1A2FOLH1NAALAD2MMP1 | |
| SCHEMBL6281449 | 0.79 | TSHR (0.48) | TSHRHSD17B10MGAMGAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111410604-B | Asymmetric hydrogenation of olefinic acid compounds | 浙江九洲药业股份有限公司 | 2023-06-16 | — | — | CN | claimed |
| JP-10298142-A | — | — | None | — | — | JP | disclosed |
| EP-3541825-B1 | CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF LIVER DISEASES | IDENIX PHARMACEUTICALS LLC (US) | 2026-04-01 | — | — | EP | disclosed |
| WO-2025137541-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| CN-119798080-A | Preparation method of (R) -5- ([ 1,1' -biphenyl ] -4-yl) -2-methyl-4-oxopentanoic acid calcium salt | 杭州科巢生物科技有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-115043721-B | Preparation method of alpha-substituted chiral carboxylic acid compound | 山东师范大学 | 2024-03-26 | — | — | CN | disclosed |
| US-11730748-B2 | Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases | MSD INTERNATIONAL GMBH (CH) | 2023-08-22 | — | — | US | disclosed |
| CN-108602785-B | Novel processes and intermediates | 诺华股份有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-115043721-A | Preparation method of alpha-substituted chiral carboxylic acid compound | 山东师范大学 | 2022-09-13 | — | — | CN | disclosed |
| US-11434192-B2 | Process and intermediates | NOVARTIS AG (CH) | 2022-09-06 | — | — | US | disclosed |
| US-4192882-A | SUBSTITUTED INDOLES FOR RELIEVING ANGIOTENSIN RELATED HYPERTENSION | E. R. SQUIBB & SONS, INC. (US) | 1980-03-11 | — | — | US | disclosed |
| US-4192881-A | RELIEVING ANGIOTENSIN RELATED HYPERTENSION | E. R. SQUIBB & SONS, INC. (US) | 1980-03-11 | — | — | US | disclosed |
| US-4154937-A | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1979-05-15 | — | — | US | disclosed |
| US-4153725-A | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1979-05-08 | — | — | US | disclosed |
| US-4146641-A | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1979-03-27 | — | — | US | disclosed |
| US-4146639-A | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1979-03-27 | — | — | US | disclosed |
| US-4128653-A | Reduction of blood pressure with carboxyalkylacyl-pipecolic acid derivatives | E. R. SQUIBB & SONS, INC. (US) | 1978-12-05 | — | — | US | disclosed |
| US-4105789-A | Carboxyalkylacylamino acids | E. R. SQUIBB & SONS, INC. (US) | 1978-08-08 | — | — | US | disclosed |
| US-4086338-A | HYPOTENSIVE AGENTS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1978-04-25 | — | — | US | disclosed |
| US-4052511-A | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1977-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730748-B2 | Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases | SLC10A1, PNP, PYGL | TSHR 2275/4885GABRR1 3650/4885CYP1A2 1025/4885 |
| US-11434192-B2 | Process and intermediates | MME, ACE, DNPEP | TSHR 3586/4885GABRR1 3882/4885CYP1A2 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.